OBJECTIVE: To assess the effect of adherence to antiretroviral therapy on the duration of virological suppression after controlling for whether or not the patient ever attained a plasma viral load below the limit of detection of sensitive HIV-1 RNA assays. METHODS: Data were combined from three randomized, blinded clinical trials (INCAS, AVANTI-2, and AVANTI-3) that compared the antiviral effects of two- and three-drug antiretroviral regimens. Virological suppression was defined as maintaining a plasma viral load below 1000 copies/mL. Adherence was defined prospectively and measured by patient self-report. RESULTS: Adherence did not have a major impact on the probability of achieving virological suppression for patients receiving dual therapy. However, for patients receiving triple therapy, adherence increased the probability of virological suppression, whether the plasma viral load nadir was above or below the lower limit of quantification. Compared to adherent patients with a plasma viral load nadir below the lower limit of quantification, the relative risk of virological failure was 3.0 for non-adherent patients with a nadir below the limit, 18.1 for adherent patients with a nadir above the limit, and 32.1 for non-adherent patients with a nadir above the limit. CONCLUSION: For patients receiving current three-drug antiretroviral regimens, adherence to therapy and plasma viral load nadir are important factors determining the duration of virological suppression.
RCT Entities:
OBJECTIVE: To assess the effect of adherence to antiretroviral therapy on the duration of virological suppression after controlling for whether or not the patient ever attained a plasma viral load below the limit of detection of sensitive HIV-1 RNA assays. METHODS: Data were combined from three randomized, blinded clinical trials (INCAS, AVANTI-2, and AVANTI-3) that compared the antiviral effects of two- and three-drug antiretroviral regimens. Virological suppression was defined as maintaining a plasma viral load below 1000 copies/mL. Adherence was defined prospectively and measured by patient self-report. RESULTS: Adherence did not have a major impact on the probability of achieving virological suppression for patients receiving dual therapy. However, for patients receiving triple therapy, adherence increased the probability of virological suppression, whether the plasma viral load nadir was above or below the lower limit of quantification. Compared to adherent patients with a plasma viral load nadir below the lower limit of quantification, the relative risk of virological failure was 3.0 for non-adherent patients with a nadir below the limit, 18.1 for adherent patients with a nadir above the limit, and 32.1 for non-adherent patients with a nadir above the limit. CONCLUSION: For patients receiving current three-drug antiretroviral regimens, adherence to therapy and plasma viral load nadir are important factors determining the duration of virological suppression.
Authors: H Knechten; C Stephan; F A Mosthaf; H Jaeger; T Lutz; A Cargnico; A Stoehr; S Koeppe; C Mayr; K Schewe; E Wolf; E Wellmann; A Tappe Journal: Infection Date: 2010-03-29 Impact factor: 3.553
Authors: Nicholas Musinguzi; Jose Castillo-Mancilla; Mary Morrow; Helen Byakwaga; Samantha Mawhinney; Tricia H Burdo; Yap Boum; Conrad Muzoora; Bosco M Bwana; Mark J Siedner; Jeffrey N Martin; Peter W Hunt; David R Bangsberg; Jessica E Haberer Journal: J Acquir Immune Defic Syndr Date: 2019-12-01 Impact factor: 3.731
Authors: Eric S Furfine; Christopher T Baker; Michael R Hale; David J Reynolds; Jo A Salisbury; Andy D Searle; Scott D Studenberg; Dan Todd; Roger D Tung; Andrew Spaltenstein Journal: Antimicrob Agents Chemother Date: 2004-03 Impact factor: 5.191
Authors: Robert Balikuddembe; Joshua Kayiwa; David Musoke; Muhammad Ntale; Steven Baveewo; Paul Waako; Celestino Obua Journal: ISRN Pharmacol Date: 2012-03-06
Authors: Robert Heglar; Rodney Mood; Julie L Priest; Kathy L Schulman; Gregory P Fusco Journal: Open Forum Infect Dis Date: 2019-09-30 Impact factor: 3.835